1283689-51-9

Upstream product

• 1283691-17-7 N-[(1R,2R)-2-(tert-butyl-dimethyl-silanyloxy)-indan-1-yl]-N-methyl-methanesulphonamide 
• 1283691-16-6 N-[(1R,2R)-2-(tert-butyl-dimethyl-silanyloxy)-indan-1-yl]-methanesulphonamide 
• 1283691-14-4 (1R,2R)-2-(tert-butyl-dimethyl-silanyloxy)-indan-1-ylamine 
• 1226992-79-5 4-(4-chloro-5-trifluoromethyl-pyrimidin-2-ylamino)-3-methoxy-N-(1-methyl-prperidin-4-yl)-benzamide 
• 1283691-18-8 N-[(1R,2R)-2-hydroxy-indan-1-yl]-N-methyl-methanesulphonamide 
• 869937-03-1 4-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzoic acid 
• 163061-73-2 (1R,2R)-1-aminoindan-2-ol 
• 41838-46-4 4-Amino-1-methylpiperidine 

Relevant academic research and scientific papers

NEW COMPOUNDS

The present invention encompasses compounds of general formulae (1a) and (1b) wherein the groups R1 to R5, A, Q, m, n, p and q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or

PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS

The present invention encompasses compounds of general formulae (1a) and (1b), wherein the groups R1 to R5, A, Q, m, n, p and q are defined as in claim 1, which are FAK/PTK2 inhibitors and thus suitable for the treatment of diseases